# A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

Study · id `cardio:ct-nct05757869` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05757869](<https://clinicaltrials.gov/study/NCT05757869>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05757869

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 20284 participants.

## Technical summary

Registry record NCT05757869. Randomized; double masking; primary purpose treatment. Start 2023-04-11 (actual); primary completion 2026-12-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 20284 participants (enrolled count; ClinicalTrials.gov record NCT05757869, source copy `cardio:ctgov-nct05757869-2026-11-03`, retrieved 2026-11-18)
- Started: 2023-04-11 (actual) (ClinicalTrials.gov record NCT05757869, source copy `cardio:ctgov-nct05757869-2026-11-03`, retrieved 2026-11-18)
- Primary completion: 2026-12-08 (anticipated) (ClinicalTrials.gov record NCT05757869, source copy `cardio:ctgov-nct05757869-2026-11-03`, retrieved 2026-11-18)
- Completion: 2026-12-08 (anticipated) (ClinicalTrials.gov record NCT05757869, source copy `cardio:ctgov-nct05757869-2026-11-03`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Chile; China; Croatia; Czechia; Denmark; Estonia; France; Germany; Greece; Hungary; India; Israel; Italy; Japan; Latvia; Lithuania; Malaysia; Netherlands; New Zealand; Philippines; Poland; Portugal; Romania; Serbia; Singapore; Slovakia; South Africa; South Korea; Spain; Taiwan; Türkiye; United Kingdom (ClinicalTrials.gov record NCT05757869, source copy `cardio:ctgov-nct05757869-2026-11-03`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05757869-2026-11-03`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
- Acronym: LIBREXIA-AF
- Condition: Atrial Fibrillation
- Intervention (Drug): Milvexian
- Intervention (Drug): Apixaban
- Intervention (Drug): Placebo
- Intervention (Drug): Apixaban Placebo
- Lead sponsor: Janssen Research & Development, LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Bristol-Myers Squibb
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry lists this organization as the lead sponsor: Janssen Research & Development, LLC (`cardio:org-janssen-research-development-llc`)
- Registry lists this organization as a collaborator: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)

## Provenance

Content hash: 39aa9854d592da7361e5b4e883b9f76fe96e7156f7b4de57164f192ac362b89d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
